Stroke, IschemicREMEDIPANCT04697979
Post-Stroke Medication Relay
An observational study of Stroke, Ischemic and Medication Compliance, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke, Ischemic, Medication Compliance
- What is being tested?
- Questionnaire
- How many people
- 54 participants
- Where
- 1 siteFrance
- Study dates
- 11 Mar 2021to 27 Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults patients managed in stroke unit following ischemic stroke who benefiting from a direct return at home.
Who may be able to join
- Adult patients managed in stroke unit following ischemic stroke
- Benefiting from a direct return home
- Non-opposition to participation
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
France1 site
Service de Neurologie Vasculaire, Unité 201 Hôpital Neurologique Pierre Wertheimer, HCL
Bron, 69677
About this study
Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects).
Improvements in the use of medications in the community and in hospital follow-up.
Telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.
- Conditions
- Stroke, Ischemic, Medication Compliance
- Being tested
- Questionnaire
- Medical subject headings
- Ischemic Stroke, Medication Adherence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
Selection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization.
Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary.
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke
The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge.
Statistical evaluation by comparative tests at one week versus two months.
Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)
Measured: 1 week
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke
The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge.
Statistical evaluation by comparative tests at one week versus two months.
Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2021
- Study start11 Mar 2021
- Primary completion27 Apr 2022
- Study completion27 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke, IschemicStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04697979
- Sponsor's protocol ID
- 69HCL20_0713
- Acronym
- REMEDIPA
- Status last verified
- Mar 2026
- First submitted
- 4 Jan 2021
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-Stroke Medication Relay
- ClinicalTrials.gov ID
- NCT04697979
- Acronym / sponsor ID
- REMEDIPA / 69HCL20_0713
- Conditions
- Stroke, Ischemic, Medication Compliance
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 11 Mar 2021 (actual)
- Primary completion
- 27 Apr 2022 (actual)
- Study completion
- 27 Apr 2022 (actual)
- First posted
- 6 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects).
Improvements in the use of medications in the community and in hospital follow-up.
Telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults patients managed in stroke unit following ischemic stroke who benefiting from a direct return at home.
Key inclusion criteria (3 listed)
- Adult patients managed in stroke unit following ischemic stroke
- Benefiting from a direct return home
- Non-opposition to participation
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireSelection of patients for a discharge interview in the stroke unit with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week and then at two months after hospitalization. Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week and then at two months after discharge. Elements on knowledge of treatment, dietary measures and warning signs and recurrence of stroke will be collected and re-explained if necessary. | Other | – |
Primary outcome
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke
Time frame: 1 week
The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge. Statistical evaluation by comparative tests at one week versus two months. Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke
Time frame: 2 months
The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge. Statistical evaluation by comparative tests at one week versus two months. Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke, Ischemic
Not yet recruiting
Short-Term External Trigeminal Nerve Stimulation for Acute Ischemic Stroke: A Sham-Controlled Trial
Acute Ischemic Stroke
Recruiting
Understanding and Enhancing Human Health and Movement
Spinal Cord Injury, Stroke (CVA) or Transient Ischemic Attack
Not yet recruitingObservational study
Detecting and Predicting Post-stroke Cognitive Impairment Using the Oxford Cognitive Screen
Stroke, Ischemic Stroke
Not yet recruitingObservational study
Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning
Stroke, Ischemic Stroke
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, Ischemic and Medication Compliance, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke (time frame: 1 week). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026; AzTrials last refreshed its copy on 3 Nov 2026.